A Randomized, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Amifampridine Phosphate in Ambulatory Patients with Spinal Muscular Atrophy (SMA) Type 3
Latest Information Update: 27 Oct 2022
At a glance
- Drugs Amifampridine (Primary)
- Indications Spinal muscular atrophy
- Focus Proof of concept; Therapeutic Use
- Sponsors Catalyst Pharmaceuticals
- 01 Nov 2022 Results published in the Journal of Neurology
- 24 Oct 2022 Primary endpoint has been met. (Hammersmith Functional Motor Scale Expanded (HFMSE) Summary Statistics and Mixed Model Analysis), as per Results published in the Journal of Neurology
- 23 Jul 2020 Status changed from recruiting to completed.